Competition in the drug market: Safe again?

Two pharmaceutical companies that have waited patiently to complete their $3.4 billion deal may proceed under strict conditions, though one Commissioner has questioned the ultimate effectiveness of the consent order....

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@mlex.com

Try FTCWatch FREE for 45 days

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch

Current Issue: 1061
Next Issue: Dec 19, 2023

Browse Archives

In this Issue:

Calendar
Lack of disclosure complicates FTC’s enforcement of influencer marketing
DOJ’s procurement collusion strike force holds first summit
US Chamber, House Republicans push FTC to strengthen recusal rules
On the Shelf: The rise and fall of the American dream
People
Justices grapple with where to draw lines on whether, when Congress can authorize agencies to bring cases without jury
Feds probe Evolv’s marketing practices
State, federal laws aimed at protecting children online upend privacy landscape
DNA testing company settles with regulators over deceptive marketing claims
Job satisfaction at FTC improves, survey says
Subspace antitrust case against Amazon highlights enforcers’ cloud competition concerns
Neil Averitt commentary: Weight-loss drugs give FTC golden opportunity
People
Judges balking at defenses about FTC’s constitutionality in preliminary injunction suits
Calendar
GOP antitrust advocate Buck to leave Congress next year
Neil Averitt commentary: Actually using a balancing test in the Google case
Ex-president of asphalt paving firm pleads guilty to rigging bids
On the Shelf: A light touch when regulating misinformation

RSS Feed